Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) saw a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 3,383,294 shares, a drop of 36.7% from the July 14th total of 5,343,969 shares. Approximately 14.0% of the company’s stock are sold short. Based on an average trading volume of 574,677 shares, the short-interest ratio is currently 5.9 days.

ADMP has been the subject of a number of recent research reports. ValuEngine raised shares of Adamis Pharmaceuticals Corporation from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 6th. Maxim Group reissued a “buy” rating and set a $10.00 price target on shares of Adamis Pharmaceuticals Corporation in a research report on Monday, June 12th.

Hedge funds have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN purchased a new stake in Adamis Pharmaceuticals Corporation during the second quarter worth $169,000. IFP Advisors Inc boosted its stake in Adamis Pharmaceuticals Corporation by 2,245.6% in the second quarter. IFP Advisors Inc now owns 34,433 shares of the specialty pharmaceutical company’s stock worth $179,000 after buying an additional 32,965 shares in the last quarter. Sterling Global Strategies LLC boosted its stake in Adamis Pharmaceuticals Corporation by 6.5% in the first quarter. Sterling Global Strategies LLC now owns 42,600 shares of the specialty pharmaceutical company’s stock worth $181,000 after buying an additional 2,600 shares in the last quarter. Virtu KCG Holdings LLC boosted its stake in Adamis Pharmaceuticals Corporation by 103.2% in the second quarter. Virtu KCG Holdings LLC now owns 38,474 shares of the specialty pharmaceutical company’s stock worth $200,000 after buying an additional 19,538 shares in the last quarter. Finally, Northern Trust Corp boosted its stake in Adamis Pharmaceuticals Corporation by 5.5% in the second quarter. Northern Trust Corp now owns 51,108 shares of the specialty pharmaceutical company’s stock worth $266,000 after buying an additional 2,686 shares in the last quarter. Institutional investors and hedge funds own 11.46% of the company’s stock.

Adamis Pharmaceuticals Corporation (NASDAQ ADMP) opened at 4.80 on Friday. The stock’s market capitalization is $132.30 million. Adamis Pharmaceuticals Corporation has a 12 month low of $2.40 and a 12 month high of $6.45. The company’s 50-day moving average is $4.96 and its 200-day moving average is $4.22.

TRADEMARK VIOLATION WARNING: This news story was originally posted by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international trademark and copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/11/short-interest-in-adamis-pharmaceuticals-corporation-nasdaqadmp-drops-by-36-7.html.

Adamis Pharmaceuticals Corporation Company Profile

Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).

Receive News & Ratings for Adamis Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.